Moderna -mRNA-1283-P301 –  COVID-19 vaccine booster

A randomized, observer-blind, active-controlled Phase 3 study to investigate the safety,
immunogenicity, and relative vaccine efficacy of mRNA-1283.222 administered as a booster
dose compared with mRNA-1273.222 in participants aged 12 years and older for the prevention
of COVID-19

Register Today!

Trial Information

Start DateMay 2023
End DateTBD
Trial Duration1 year
Number of Visits9
Lead CRCMarija Bernstein
StatusIn Start-up

For additional information
on this trial contact: